Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Push for More Drugs for Deadly, Rare Diseases

April 27, 2011 7:16 am | by Lauran Neergaard | News | Comments

Every other week, 7-year-old twins Addison and Cassidy Hempel have an experimental medicine injected into their spines in hopes of battling a rare, fatal disease. And it's their mom who made that possible.


Hospira Income Up 6% in First Quarter

April 27, 2011 7:12 am | News | Comments

Drug and medical device maker Hospira Inc. said its net income rose 6 percent in the first quarter on strong sales of new products, including generic versions of the cancer drugs Gemzar and Taxotere.


Medtronic, Eli Lilly Collaborate on Parkinson's

April 27, 2011 7:09 am | News | Comments

Medical device maker Medtronic and drugmaker Eli Lilly said they will collaborate on an implantable drug delivery system to treat Parkinson's disease, the debilitating brain disorder that causes tremors and movement problems.


What to Expect from BMS

April 27, 2011 7:08 am | News | Comments

Drugmaker Bristol-Myers Squibb Co., which recently got approval of an important new skin cancer drug but is facing a sharp revenue drop next year, will report first-quarter results before the stock market opens Thursday.


Regeneron Cancer Drug Meets Study Goals

April 27, 2011 7:05 am | News | Comments

Regeneron Pharmaceuticals Inc. and partner Sanofi-Aventis' potential cancer drug met key goals in a late-stage study focusing on colon cancer patients.


Merck Approves $5B in Stock Buybacks

April 27, 2011 7:02 am | News | Comments

Merck & Co. Inc. said its board of directors approved the buyback of up to $5 billion in common stock for the drug developer's treasury. Overall, the company is now authorized to buy back up to $6.4 billion in common stock.


J & J Buying Synthes for $21.3B

April 27, 2011 6:59 am | by Frank Jordans | News | Comments

Health products giant Johnson & Johnson said it will buy U.S.-Swiss medical device maker Synthes Inc. for $21.3 billion, greatly increasing its share of the market for surgical trauma equipment and orthopedic implants.


API Toolkit

April 26, 2011 8:31 am | Product Releases | Comments

Sage-N Research, Inc. announced a new API toolkit for developers of proteomics data analysis software. The toolkit will enable software developers to add the power and sensitivity of SORCERER analyses to their existing software packages.


Syringe Pumps

April 26, 2011 8:29 am | Drug Discovery & Development | Product Releases | Comments

Harvard Apparatus has introduced a new line of OEM Syringe Pumps designed for specialized solutions for a variety of fluid handling applications to meet fluidics research requirements.


KemPharm Working With MonoSol on ADHD Treatment

April 26, 2011 8:22 am | News | Comments

KemPharm, Inc. announced that KP106 will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.


Eppendorf Opens Neurobiology Contest

April 26, 2011 8:19 am | News | Comments

Eppendorf and the world-renowned journal Science are now accepting applications for the 2011 Eppendorf & Science Prize for Neurobiology. The Eppendorf & Science Prize for Neurobiology is an annual international research prize of US$ 25,000.


High Omega-3 Levels May Boost Cancer Risk

April 26, 2011 8:10 am | News | Comments

The largest study ever to examine the association of dietary fats and prostate cancer risk has found what's good for the heart may not be good for the prostate.


New Drug Class Could Take on Colon Cancer

April 26, 2011 8:07 am | News | Comments

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study has found.


Kuros Candidate Reduces Healing Time

April 26, 2011 8:04 am | News | Comments

Kuros Biosurgery AG, announced that KUR-113 met the primary efficacy endpoint in a 200 patient Phase 2b clinical trial designed to assess its efficacy and safety in open tibial shaft fracture patients.


FDA Approves DUEXIS for Arthritis

April 26, 2011 7:54 am | News | Comments

Horizon Pharma, Inc. announced that the U.S. Food and Drug Administration has approved DUEXIS, a novel tablet formulation containing a fixed-dose combination of ibuprofen and famotidine.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.